FDA authorizes AstraZeneca antibody cocktail for pre-exposure prevention of COVID-19

FDA authorizes AstraZeneca antibody cocktail for pre-exposure prevention of COVID-19

The FDA has for the first time approved an emergency use authorization for a long-acting monoclonal antibody cocktail designed to prevent symptomatic COVID-19 among adults and children aged 12 years and older.According to data submitted to the FDA, AstraZeneca’s Evusheld (tixagevimab plus cilgavimab), also known as AZD7442, can reduce the risk for developing symptomatic COVID-19 by 77%, compared with placebo, among unvaccinated adults without prior SARS-CoV-2 infection at increased risk for inadequate immunization response.Alfred H.J. Kim, MD, PhD, assistant professor of medicine in theRead More

Share on facebook
Share on twitter
Share on linkedin